Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands.
Gastrointest Endosc. 2010 Aug;72(2):249-54. doi: 10.1016/j.gie.2010.01.070. Epub 2010 May 26.
Despite advances in staging methods, surgical techniques, and adjuvant treatment, recurrent cancer after esophagectomy is a major cause of morbidity and mortality.
Our purpose was to investigate the safety and efficacy of a self-expandable metal stent (SEMS) in patients with dysphagia or fistula caused by recurrent cancer after esophagectomy.
Prospective, observational study with standardized treatment and follow-up.
Single university center.
In 81 patients with recurrent cancer after previous surgical esophagectomy, 100 esophageal SEMSs were inserted for dysphagia (n = 66) or fistula formation (n = 15).
Stent placement.
Technical and functional outcome, complications, and survival.
The SEMSs restored luminal patency in 65 (98%) of 66 patients and sealed malignant fistulae in 14 (93%) of 15 patients. Stent dysfunction occurred in 24 (30%) of 81 patients. They all were successfully managed by subsequent endoscopic intervention. After stent placement, a total of 16 complications were observed. Major complications occurred in 9 (11%) of 81 patients, mild complications occurred in 7 (9%) of 81 patients. The overall 30-day mortality rate after stent insertion was 25%. Progression of the disease resulted in death after a median interval of 70 days (range 1 day to 91 months).
Nonrandomized design.
SEMS placement in recurrent esophageal cancer after surgical resection offers adequate palliation by relieving dysphagia and sealing off esophageal respiratory fistulae. Therefore, in these patients who have a relatively short life expectancy, SEMS placement should be considered the treatment of choice.
尽管在分期方法、手术技术和辅助治疗方面取得了进展,但食管癌切除术后复发仍是发病率和死亡率的主要原因。
我们旨在研究自膨式金属支架(SEMS)在食管癌切除术后复发引起的吞咽困难或瘘管患者中的安全性和有效性。
前瞻性、观察性研究,采用标准化治疗和随访。
单所大学中心。
在 81 例先前接受过手术治疗的食管癌切除术后复发的患者中,为 66 例吞咽困难和 15 例瘘管形成患者共插入了 100 个食管 SEMS。
支架放置。
技术和功能结果、并发症和生存情况。
SEMS 在 66 例患者中的 65 例(98%)恢复了管腔通畅性,在 15 例患者中的 14 例(93%)中封闭了恶性瘘管。81 例患者中有 24 例(30%)发生支架功能障碍,均通过随后的内镜干预成功处理。支架放置后共观察到 16 种并发症。81 例患者中有 9 例(11%)发生严重并发症,7 例(9%)发生轻度并发症。支架插入后 30 天的总死亡率为 25%。疾病进展导致中位间隔 70 天(范围 1 天至 91 个月)后死亡。
非随机设计。
在外科切除术后复发的食管癌症患者中,SEMS 放置通过缓解吞咽困难和封闭食管呼吸瘘管提供了充分的姑息治疗。因此,在这些预期寿命相对较短的患者中,应考虑将 SEMS 放置作为首选治疗方法。